1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  05/27 11:31:39 am EDT
87.12 CHF   -0.80%
05/24Humber Industrials Ltd agreed to acquire 170-acre active pharmaceutical ingredient manufacturing plant site and assets in Grimsby, UK from Novartis AG.
CI
05/23Dividend payouts hit first quarter record, but outlook rocky
RE
05/20Novartis' Cosentyx Recommended by EU Committee for Approval in Juvenile Arthritis
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : Goldman Sachs gives a Buy rating

01/25/2022 | 01:16pm EDT

Goldman Sachs analyst Keyur Parekh maintains his Buy rating on the stock. No major update to the target price set at CHF 106 compared to CHF 105.


© MarketScreener with dpa-AFX Analyser 2022
All news about NOVARTIS AG
05/24Humber Industrials Ltd agreed to acquire 170-acre active pharmaceutical ingredient manu..
CI
05/23Dividend payouts hit first quarter record, but outlook rocky
RE
05/20Novartis' Cosentyx Recommended by EU Committee for Approval in Juvenile Arthritis
MT
05/20Novartis Cosentyx(R) (secukinumab) receives positive CHMP opinion for expanded use in c..
DJ
05/20Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in chi..
GL
05/20Novartis Cosentyx (secukinumab) receives positive CHMP opinion for expanded use in chil..
CI
05/20Cancer coalition aims to boost access to medicines in poorer countries
RE
05/16GLOBAL MARKETS LIVE : Pfizer, Tesla, Holcim, Novartis, Ford...
05/13Avantor Names Jonathan Peacock Chairman
MT
05/13EQT pushes back Galderma IPO plans amid market turmoil - sources
RE
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 52 802 M - -
Net income 2022 9 263 M - -
Net Debt 2022 6 931 M - -
P/E ratio 2022 20,5x
Yield 2022 3,66%
Capitalization 198 B 198 B -
EV / Sales 2022 3,88x
EV / Sales 2023 3,73x
Nbr of Employees 110 000
Free-Float 88,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 91,10 $
Average target price 94,75 $
Spread / Average Target 4,00%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG8.52%197 864
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098